Ultrasound (HEAD-US) score can help standardize monitoring in haemophilia. This study evaluated the joint status (elbows, knees and ankles) of patients with haemophilia B (HB) in Spain using MSK-US and the HEAD-US score.
| INTRODUC TI ON
Haemophilic arthropathy accounts for 75% of the complications of haemophilia, and is increasingly important in the present medical setting, where major advances in treatment have considerably increased patients' life expectancy. [1] [2] [3] Clinical assessment of joints in HB is commonly performed by physical examination, 4 and radiological examination should be performed annually or as indicated. 5 In practice, diagnostic imaging is frequently not obtained in the initial stages of arthropathy, for reasons that include lack of access to radiological services or difficulty in justifying the referral of often asymptomatic patients. MRI is presently considered the gold standard for arthropathy assessment, [6] [7] [8] [9] [10] but it has some drawbacks, namely its lack of availability, high cost, inability to evaluate more than one joint in a single study, and the requirement of patient immobilization within the magnet for long periods of time, with sedation in the case of children (meaning added risks and costs). 11 In contrast, musculoskeletal ultrasound (MSK-US) has shown enormous progress in recent years, and has been found to be exceptionally useful as a tool for basic diagnoses in soft tissues. [12] [13] [14] [15] [16] [17] [18] [19] Its use in the diagnosis and evaluation of the early stages of haemophilic arthropathy was described for the first time in 1992 by Merchan et al 20 and since then MSK-US has shown excellent results in depicting disease-specific findings, including haemarthrosis episodes and their evolution, 16, 17, 21, 22 persistence of changes beyond apparent healing, 23 chronic synovial proliferation and articular cartilage and subchondral bone damage. 17, 24, 25 The HEAD-US scoring system 15 was designed to provide a means to follow-up the joint status longitudinally, in order to assess the results of treatment and to measure outcomes.
It is intended to be used as a point-of-care tool by non-imaging experts, 25 and can greatly minimize operator-dependency since it is based on a straightforward protocol which has been developed to allow joint assessment by non-radiologists.
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The aim of this study was twofold: (a) to screen the elbows, knees and ankles in the HB population of Spain using MSK-US; and (b) to explore the relationship of joint status with disease type and treatment strategy.
| MATERIAL S AND ME THODS
An observational, cross-sectional study was conducted in 12 Spanish hospitals. All patients signed an informed consent for participation. 
| PATIENTS
The sample enrolled patients with haemophilia B aged ≥14 years who had accepted a previous invitation to participate in the study and attended their scheduled visit in their respective referral centre within the inclusion period (17 Nov 2014 to 22 Feb 2016 . All patients meeting the age criterion were invited to participate, and those that agreed were included regardless of their clinical condition, severity of haemophilia and treatment received. Only patients with significant physical disability for ultrasound scanning were excluded.
| PROCEDURE S
All MSK-US studies were performed in a single visit with a portable ultrasound machine (MyLabOne; Esaote, Genoa, Italy) equipped with a broadband linear array transducer (frequency band, 13-4 MHz). For statistical analysis, a final score was assigned to each patient after consensus of examiners. 
| VARIAB LE S AND DEFINITI ON S

| S TATIS TI C AL ME THODS
Since HB is a rare disease with very low prevalence, convenience sam- severe disease had a HEAD-US score = 0-1 ( Table 2) . Differences between severity groups were statistically significant in most joints ( Table 2) 
| RE SULTS
| HEAD-US scores and treatment modality
Since joint status was significantly worse in patients treated on demand, compared to those on prophylaxis, we further analysed the individual items of the HEAD-US score in these patients, finding presence of disease activity and permanent damage, significantly worse with disease severity (see Tables S1 and S2 ). Treatment modality also had an impact on joint health. Patients on PP or SP had better scores in all joints than those treated OD, and patients on TP had the highest mean scores ( Figure 2A ). Comparing patients on PP plus SP with patients treated OD, scores were significantly better in all joints among patients on prophylaxis (p < 0.05), except for the right ankle (p = 0.125; Figure 2B ). Three joints not scored due to prosthetic implants.
TA B L E 2 Comparison of frequencies of HEAD-US scores by haemophilia B severity
Patients treated OD (n = 49) were also analysed separately to assess the effect of HB severity. Patients with severe HB treated OD had significantly worse mean HEAD-US scores in all joints compared to patients with mild or moderate disease (Figure 3 ).
| HEAD-US scores and disease activity
With respect to grade 2 (severe) synovitis as a hallmark of uncontrolled disease, this was found in one or more joints in 18% of patients (n = 9/49 cases) treated OD and in 21% of patients (n = 7/33 cases) on prophylaxis (Table 3) . From this latter group, grade 2 synovitis was encountered in patients who received PP (n = 3/6), SP (n = 1/18) and TP (n = 3/9).
Considering grade 1 (mild, moderate) and grade 2 synovitis together, in the total population with signs of disease activity, 57% of patients (n = 28/49) were treated OD and 48% of patients (n = 16/33) were on prophylaxis. Among the latter, 3/6 cases were on PP, 6/18 on SP and 7/9 on TP. Even excluding TP, the percentage of patients on PP and SP with grade 2 synovitis remained high, accounting for 16%, whereas those presenting with grade 1 and/or grade 2 synovitis was 45% (Table 3 ).
| Logistic regression analysis
Multivariate analysis performed to determine the influence of age, disease severity and treatment modality (prophylaxis or on demand)
in joint status according to the HEAD-US score showed that increasing age and severity of disease were generally related to an increased odds ratio for having a score above 1, while the type of treatment had a significant odds ratio for the right knee only ( Table 4 ). The linear model tested with these variables fitted the score in the right knee and both ankles, while goodness of fit was poor in the other three joints. A linear model for all three of these variables could be adjusted in all joints except for the right elbow. Despite changing practices in HB treatment, a notably high proportion of the overall cohort has healthy joints (HEAD-US score 0-1) F I G U R E 3 HEAD-US score of each joint according to haemophilia severity in patients treated on demand (OD). Joint health worsened significantly in all cases as severity increased. Severe HB was significantly different from the other two severity groups in all cases, except in the left knee, where the difference was significant only between mild and severe HB OD, on demand; PP, primary prophylaxis; SP, secondary prophylaxis; TP, tertiary prophylaxis Data refer to the number (percentage) of patients who had one or more joints involved.
TA B L E 3
Synovitis in the population of HB patients according to treatment option but, the more severe the condition, the poorer the score in all joints. This is not surprising considering the natural history of HB, but our findings suggest that the treatment option greatly affects joint status, and that patient on PP and SP had significantly better scores than patients treated OD, regardless of HB severity. Logistic regression revealed that age had a significant influence (odds ratio) on having a score >1 point. HEAD-US score was coded as '0-1' vs '>1' (as results with more categories were inconsistent due to overflow). Reference category was '0-1' for the odds ratio. Age was numeric, in years (see Table S2 ).
Prophylaxis (primary [PP], secondary [SP] and tertiary [TP]
) was compared to on-demand (OD) treatment. Treatment regimen was coded as PP-SP-TP vs OD (Table S2 ). Reference category was OD for the odds ratio. Haemophilia B severity was coded as Mild, Moderate and Severe (Table S2) . Mild was the reference category for the odds ratio. Hosmer-Lemeshow Goodness of Fit test was performed to assess the fit of a linear model. In this model, non-significant p-values indicate that the model is adjusted.
although a future study following this younger cohort would be needed to establish the actual difference introduced by treatment modality.
Nonetheless, joint health of patients with severe HB treated OD is poor, compared to patients with less severe disease (Figure 3 ), which confirms that prophylaxis is more effective at preserving joint function.
Moreover, patients on TP had the worst HEAD-US scores, which is an expected feature given that TP is usually initiated when joint bleeds become highly recurrent and joint health is poor. Earlier consideration of TP, before joint destruction has become so substantial, might slow the progression of arthropathy. Haemophilia patients now have a long-life expectancy, and joint health is key to maintaining a good quality of life over their lifetime. Early detection of joint deterioration and establishment of an adequate treatment strategy is most desirable, along with bleeding prevention through early prophylaxis. 5, 36, 37 In this regard, appropriate assessment with imaging tools plays a role, We believe that implementation of a point-of-care ultrasound protocol that can be routinely used in the haemophilia clinic might improve these figures and patient care. This study demonstrates that MSK-US examination can be readily performed with a portable machine in any haemophilia context, and that the HEAD-US system can be performed by non-imaging specialists after a short training course for proper assessment.
Of course, MSK-US also has intrinsic limitations. Different from MRI, ultrasound cannot provide a comprehensive evaluation of the osteochondral surfaces or detect haemosiderin deposits. Moreover, despite MSK-US is highly sensitive to detect the presence of soft tissue alterations, it has been proved that it is not able to discriminate between synovial, fatty or blood tissue types. Our study represents a novel approach to the epidemiology of haemophilic arthropathy in HB patients, with a considerable sample size given the low prevalence of this condition and provides new insight on the joint status of HB patients and the effect of treatment decisions.
Its strength lies in the participation of the most relevant centres across the country treating HB patients and assessment by the same three operators in all these centres, using the HEAD-US protocol and scoring system. For logistic reasons, clinical scores were not recorded to be compared with the ultrasound assessment, and analysis of agreement between HEAD-US and clinical scores is beyond the scope of this paper. In addition, the sampling method may have introduced some bias regarding patient characteristics, but the cohort as a whole is representative of the Spanish HB population.
| CON CLUS ION
In conclusion, joint status of HB patients in Spain is better in those following prophylaxis compared to those treated on demand or who started prophylaxis when they had established arthropathy (tertiary prophylaxis). Signs of disease activity were detected in a considerable number of HB patients treated OD and on prophylaxis, suggesting the 
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